Tempest Therapeutics, Inc. (TPST)Healthcare | Biotechnology | Brisbane, United States | NasdaqCM
0.98 USD
+0.01
(1.079%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.00 +0.02 (1.678%) ⇧ (July 13, 2026, 7:37 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:01 a.m. EDT
The immediate outlook is severely bearish as the stock trades near its 52-week low of $0.95, having recently collapsed from a $1.25 peak just weeks ago. This sharp intraday and weekly decline confirms a breakdown in the short-term trend, leaving little room for a bounce given the heavy selling pressure. Looking further ahead, the business fundamentals are in freefall; the company has endured nearly a decade of destruction, with the share price erasing 99.96% of its value since 2016. The most recent annual period saw another catastrophic drop of roughly 75%, indicating that the market has repeatedly rejected the company's value proposition. Compounding this distress is a precarious balance sheet where debt nearly ten times the book value and negative free cash flow suggest the company is burning through capital without generating returns. There is no dividend to provide any income cushion, and the lack of analyst coverage reflects a consensus that the investment thesis has broken down completely. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.173565 |
| AutoARIMA | 0.224854 |
| AutoETS | 0.224854 |
| MSTL | 0.226645 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.082 |
| Excess Kurtosis | -1.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 955.474 |
| Market Cap | 15,715,751 |
| Forward P/E | -0.81 |
| Beta | -1.71 |
| Previous Name | Tempest Therapeutics Inc. |
| Website | https://www.tempesttx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.85898554 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 400 |
| All Time High | 162,893.25 |
| All Time Low | 0.95 |
| Ask | 1.28 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 106,570 |
| Average Daily Volume3 Month | 161,729 |
| Average Volume | 161,729 |
| Average Volume10Days | 106,570 |
| Beta | -1.707 |
| Bid | 0.749 |
| Bid Size | 2 |
| Book Value | 0.057 |
| City | Brisbane |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9835 |
| Current Ratio | 0.739 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.075 |
| Day Low | 0.9734 |
| Debt To Equity | 955.474 |
| Display Name | Tempest Therapeutics |
| Dividend Date | 1,544,400,000 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -20,920,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.985 |
| Enterprise Value | 20,611,682 |
| Eps Current Year | -1.34 |
| Eps Forward | -1.21 |
| Eps Trailing Twelve Months | -5.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.49362 |
| Fifty Day Average Change | -0.51012003 |
| Fifty Day Average Change Percent | -0.34153268 |
| Fifty Two Week Change Percent | -85.89855 |
| Fifty Two Week High | 12.23 |
| Fifty Two Week High Change | -11.2465 |
| Fifty Two Week High Change Percent | -0.919583 |
| Fifty Two Week Low | 0.95 |
| Fifty Two Week Low Change | 0.033500016 |
| Fifty Two Week Low Change Percent | 0.035263173 |
| Fifty Two Week Range | 0.95 - 12.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,730,600,000 |
| Float Shares | 9,731,603 |
| Forward Eps | -1.21 |
| Forward P E | -0.8128099 |
| Free Cashflow | -16,625,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31781 |
| Held Percent Institutions | 0.26399 |
| Implied Shares Outstanding | 15,979,411 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,156,800 |
| Last Split Factor | 1:13 |
| Long Business Summary | Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. |
| Long Name | Tempest Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 15,715,751 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_552715229 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -43,098,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 15,547,966 |
| Number Of Analyst Opinions | 1 |
| Open | 0.9993 |
| Operating Cashflow | -26,382,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 415 798 8589 |
| Post Market Change | 0.016499996 |
| Post Market Change Percent | 1.6776813 |
| Post Market Price | 1.0 |
| Post Market Time | 1,783,985,855 |
| Prev Name | Tempest Therapeutics Inc. |
| Previous Close | 0.973 |
| Price Eps Current Year | -0.7339552 |
| Price Hint | 4 |
| Price To Book | 17.254387 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.545 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0105 |
| Regular Market Change Percent | 1.07914 |
| Regular Market Day High | 1.075 |
| Regular Market Day Low | 0.9734 |
| Regular Market Day Range | 0.9734 - 1.075 |
| Regular Market Open | 0.9993 |
| Regular Market Previous Close | 0.973 |
| Regular Market Price | 0.9835 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 425,771 |
| Return On Assets | -0.61689997 |
| Return On Equity | -7.21004 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,979,411 |
| Shares Percent Shares Out | 0.0178 |
| Shares Short | 284,764 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 341,334 |
| Short Name | Tempest Therapeutics, Inc. |
| Short Percent Of Float | 0.0381 |
| Short Ratio | 1.68 |
| Source Interval | 15 |
| State | CA |
| Symbol | TPST |
| Target High Price | 11.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 1,805,000 |
| Total Cash Per Share | 0.122 |
| Total Debt | 7,854,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.833605 |
| Two Hundred Day Average Change | -2.850105 |
| Two Hundred Day Average Change Percent | -0.74345297 |
| Type Disp | Equity |
| Volume | 425,771 |
| Website | https://www.tempesttx.com |
| Zip | 94,005 |